ATGC, a local biopharmaceutical firm, said that the Ministry of Food and Drug Safety has approved its phase 1 and 2 clinical trial for ATGC-110, botulinum toxin (BTX) product.
"With the approval, it has become highly possible that our ATGC-110 will become the world's third pure botulinum toxin A, following Xeomin and Coretox," the company said. "ATGC-110 is a product made by purifying 150kDa pure toxin protein after removing the non-toxic proteins."
|ATGC's BTX ATGC-110|
It is a product that has secured safety by maintaining the efficacy and reducing the possibility of resistance, the company added.
The company also stressed that it had proved its technology as a biopharmaceutical R&D company now that it has entered the clinical stage before any other leading biopharmaceutical companies in Korea.
"ATGC's core growth strategy is to secure diverse and innovative pipelines through intensive investment in R&D," said Kim Sang-wook, head of ATGC's management division. "The company is also preparing for the EU clinical trial of ATGC-100 and is in talks with European CMO companies for its production in Europe."
Negotiations are also underway with large overseas pharmaceutical companies for copyright rights in Europe and China, Kim added.
<© Korea Biomedical Review, All rights reserved.>